You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國同輻(01763.HK):原子高科治療用碘化鈉膠囊成功進入最新國家醫保藥品目錄
格隆匯 12-14 16:34

格隆匯12月14日丨中國同輻(01763.HK)公佈,12月13日,國家醫保局、人力資源和社會保障部聯合印發《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)》,新版國家醫保藥品目錄將於2024年1月1日起在全國範圍內正式執行。

原子高科生產的治療用碘[131I]化鈉膠囊經過資料申報、形式審查、專家評審、現場談判等環節,以國家醫保談判藥品的身份順利進入新版國家醫保藥品目錄。治療用碘[131I]化鈉膠囊臨牀上用於甲狀腺功能亢進症、可攝碘的甲狀腺癌以及可攝碘的甲狀腺癌轉移灶的治療。以膠囊形式給病人用藥,藥物可直接到達患者胃部,避免了放射性碘[131I]易粘附在病人的口腔、鼻腔、食道等部位而引起的副作用;並且膠囊劑使用簡便,可省去分裝碘[131I]化鈉口服溶液的過程,減少揮發性放射性污染、降低對工作人員的輻射。

治療用碘[131I]化鈉膠囊成功進入國家醫保藥品目錄,不僅進一步提高該藥品的可及性,切實減輕患者經濟負擔,同時對滿足現行輻射安全管理要求,解決放射性藥品生產和使用單位的發展瓶頸,促進國內核醫學健康可持續發展具有重要意義。

今後,原子高科將一如既往秉持"以人民為中心",堅持弘揚"強核報國,創新奉獻"的新時代核工業精神,立足"三新一高"新發展階段,持續打造科技創新核心競爭力,助力健康中國。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account